Literature DB >> 26689224

Absence of adverse events in healthy individuals using probiotics--analysis of six randomised studies by one study group.

L Tapiovaara1, L Lehtoranta2, T Poussa3, H Mäkivuokko4, R Korpela2, A Pitkäranta1.   

Abstract

Consumption of live bacteria as probiotic supplements is increasing. There is, however, a lack of information on the safety of ingested probiotics. The main objective of this study was to investigate the adverse events (AEs) of specific probiotics (Lactobacillus rhamnosus GG (LGG) alone or LGG in combination with L. rhamnosus Lc705, Propionibacterium freudenreichii JS, Bifidobacterium lactis BB12, or Bifidobacterium breve 99) studied in six of our study groups' clinical trials, by analysing individual participant data. A secondary objective was to study AEs associated with the consumed probiotic species and mixtures in three specific categories; 'gastrointestinal disorders', 'respiratory, thoracic and mediastinal disorders' and 'infections and infestations'. Six randomised, double-blind, placebo-controlled clinical studies by our study group were included in this AE analysis (study population n=1,909). All AE data were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v4.0. From the 26 CTCAE System Organ Classes, we identified AEs in 20 classes among 1,909 subjects. Probiotic ingestion did not result in statistically significant differences in AEs in different groups, when compared to placebo. A subgroup analysis of gastrointestinal, respiratory, thoracic and mediastinal disorders, infections and infestations, found no differences between the intervention groups or for different probiotic combinations (risk ratio (RR) = 0.97, 95% confidence interval (CI): 0.93-1.02, P=0.30; RR=0.99, 95% CI: 0.97-1.01, P=0.35; RR=0.99, 95% CI: 0.93-1.06, P=0.62, respectively). As a conclusion, ingestion of probiotic supplementations containing LGG alone, or LGG in combination with L. rhamnosus Lc705, P. freudenreichii JS, B. breve 99, or B. lactis BB12 did not seem to cause AEs in young and elderly subjects in this analysis.

Entities:  

Keywords:  Bifidobacterium; Lactobacillus; probiotics; safety

Mesh:

Year:  2015        PMID: 26689224     DOI: 10.3920/BM2015.0096

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  9 in total

Review 1.  The role of topical probiotics on wound healing: A review of animal and human studies.

Authors:  Rebecca Knackstedt; Thomas Knackstedt; James Gatherwright
Journal:  Int Wound J       Date:  2020-08-31       Impact factor: 3.315

Review 2.  International Society of Sports Nutrition Position Stand: Probiotics.

Authors:  Ralf Jäger; Alex E Mohr; Katie C Carpenter; Chad M Kerksick; Martin Purpura; Adel Moussa; Jeremy R Townsend; Manfred Lamprecht; Nicholas P West; Katherine Black; Michael Gleeson; David B Pyne; Shawn D Wells; Shawn M Arent; Abbie E Smith-Ryan; Richard B Kreider; Bill I Campbell; Laurent Bannock; Jonathan Scheiman; Craig J Wissent; Marco Pane; Douglas S Kalman; Jamie N Pugh; Jessica A Ter Haar; Jose Antonio
Journal:  J Int Soc Sports Nutr       Date:  2019-12-21       Impact factor: 5.150

3.  Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials.

Authors:  P Baindara; R Chakraborty; Z M Holliday; S M Mandal; A G Schrum
Journal:  New Microbes New Infect       Date:  2021-01-06

Review 4.  Biological and Psychological Factors Determining Neuropsychiatric Outcomes in COVID-19.

Authors:  Boris N Tizenberg; Lisa A Brenner; Christopher A Lowry; Olaoluwa O Okusaga; David R Benavides; Andrew J Hoisington; Michael E Benros; John W Stiller; Ronald C Kessler; Teodor T Postolache
Journal:  Curr Psychiatry Rep       Date:  2021-10-01       Impact factor: 5.285

5.  Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli.

Authors:  Sarah Lebeer; Eline F M Oerlemans; Ingmar Claes; Tim Henkens; Lize Delanghe; Sander Wuyts; Irina Spacova; Marianne F L van den Broek; Ines Tuyaerts; Stijn Wittouck; Ilke De Boeck; Camille N Allonsius; Filip Kiekens; Julien Lambert
Journal:  Cell Rep Med       Date:  2022-02-15

Review 6.  Evaluating the Role of Probiotics in the Prevention and Management of Age-Related Diseases.

Authors:  Despoina E Kiousi; Antonia Z Kouroutzidou; Konstantinos Neanidis; Dimitrios Matthaios; Aglaia Pappa; Alex Galanis
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

Review 7.  Probiotics in the Management of Mental and Gastrointestinal Post-COVID Symptomes.

Authors:  Igor Łoniewski; Karolina Skonieczna-Żydecka; Joanna Sołek-Pastuszka; Wojciech Marlicz
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

Review 8.  Probiotics and COVID-19: is there any link?

Authors:  A Akour
Journal:  Lett Appl Microbiol       Date:  2020-07-16       Impact factor: 2.813

9.  Role of Probiotics in Stimulating the Immune System in Viral Respiratory Tract Infections: A Narrative Review.

Authors:  Liisa Lehtoranta; Sinikka Latvala; Markus J Lehtinen
Journal:  Nutrients       Date:  2020-10-16       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.